智通财经APP讯，福然德(605050.SH)发布公告，公司控股股东、实际控制人的一致行动人暨持股5%以 上股东宁波人科创业投资合伙企业(有限合伙)(简称"人科合伙")计划减持公司股份数量不超过1478.49万 股，合计减持比例不超过公司股份总数的3%。 ...

福然德12月1日晚间公告，公司控股股东、实际控制人的一致行动人暨持股5%以上股东宁波人科创业投 资合伙企业（有限合伙）计划自公告披露之日起15个交易日后的3个月内，通过集中竞价交易方式减持 公司股份不超过492.83万股，即不超过公司总股本的1%；通过大宗交易方式减持公司股份不超过985.66 万股，即不超过公司总股本的2%。合计减持不超过1478.49万股，即不超过公司总股本的3%。减持原因 为自身资金需求。本次减持计划实施具有不确定性。 ...

重要内容提示： 证券代码：605050 证券简称：福然德 公告编号：2025-054 福然德股份有限公司 关于控股股东、实际控制人的一致行动人 暨持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 控股股东、实际控制人的一致行动人暨持股 5%以上股东持股的基本情况： 本次减持主体为福然德股份有限公司（以下简称"公司"）控股股东、实际控制 人的一致行动人暨持股 5%以上股东宁波人科创业投资合伙企业（有限合伙）（以 下简称"人科合伙"）。截至本公告日，人科合伙持有公司无限售条件流通股 123,750,000 股，占公司总股本的 25.11%，股份来源为公司首次公开发行前取得， 该部分股份已于 2023 年 9 月 25 日解除限售并上市流通。 减持计划的主要内容：公司于 2025 年 12 月 1 日收到人科合伙出具的《关 于减持福然德股份有限公司股份计划的告知函》。因自身资金需求，人科合伙计 划自本公告披露之日起 15 个交易日后的 3 个月内通过集中竞价交易方式及大宗 交易方式减持公 ...

人民财讯12月1日电，福然德（605050）12月1日公告，公司控股股东、实控人的一致行动人暨持股5% 以上股东宁波人科创业投资合伙企业(有限合伙)计划15个交易日后的3个月内，通过集中竞价交易方式 及大宗交易方式，减持公司股份合计不超过1478.49万股，减持比例不超过公司股份总数的3%。 ...

福然德股份有限公司 2025 年第三次临时股东会会议资料 福然德股份有限公司 2025 年第三次临时股东会 会议资料 中国•上海 2025 年 12 月 1 / 7 福然德股份有限公司 2025 年第三次临时股东会会议资料 福然德股份有限公司 2025 年第三次临时股东会会议须知 各位股东： 为维护全体股东的合法权益，确保福然德股份有限公司（以下简称"公司"） 股东会的正常秩序和议事效率，保证大会顺利进行，公司根据《中华人民共和国 公司法》、《上市公司股东会规则》、《公司章程》等有关规定，制定本须知。 一、公司负责本次会议的程序安排和会务工作，出席会议人员应当听从工作 人员安排，共同维护好会议秩序。 二、为保证本次会议的正常秩序，除出席会议的股东及股东代表、董事、监 事、董事会秘书、高级管理人员以及见证律师以外，公司有权拒绝其他人员进入 会场。对于影响本次会议秩序和损害其他股东合法权益的行为，公司将按规定加 以制止。 三、参会股东及股东代理人（以下简称"股东"）须携带身份证明文件及相 关授权文件办理会议登记手续及有关事宜。股东持有效证件完成会议登记后领取 会议资料。 四、参会股东应当按照会议通知时间准时到场， ...

Group 1 - The core point of the article is that Furan De (SH 605050) announced government subsidies totaling 34.655 million yuan, which will significantly impact its financial performance for the year 2024 [1] - The government subsidies include 23.355 million yuan related to income and 11.3 million yuan related to assets, accounting for 10.94% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1] - For the year 2024, Furan De's revenue composition shows that supply chain services account for 99.93% of total revenue, while other businesses contribute only 0.07% [1] Group 2 - As of the report, Furan De has a market capitalization of 6.6 billion yuan [2]

证券日报网讯 11月24日晚间，福然德发布公告称，2025年1月1日至2025年11月24日，公司收到政府补 助资金3，465.50万元，其中与收益相关的政府补助资金2，335.50万元，与资产相关的政府补助资金1， 130.00万元，占公司2024年度经审计归属于上市公司股东净利润的10.94%。 （文章来源：证券日报） ...

Group 1 - The company, Furan De, announced a profit distribution plan for the mid-term of 2025, proposing a cash dividend of 2.00 yuan (including tax) for every 10 shares to all shareholders [2] - The dividend distribution will be based on the total share capital after deducting the number of shares repurchased and held in the repurchase special account [2] - The announcement was made on the evening of November 24 [2]

Group 1 - Huafeng Co., Ltd. announced a stock suspension due to a potential change in control after signing a share transfer intention agreement [1] - Keshida plans to reduce its shareholding by up to 424,000 shares, representing 0.07% of its total share capital [1] - Jinqilin intends to distribute a cash dividend of 0.10 yuan per share, totaling 19.61 million yuan [1] Group 2 - Rejingshi Biotech has repurchased 904,100 shares, accounting for 0.98% of its total share capital, with a total expenditure of 150 million yuan [2] - Yishitong has repurchased 1,236,500 shares, representing 0.619% of its total share capital, with a total expenditure of approximately 33.49 million yuan [2] Group 3 - Hanjia Design announced the release of a detention on its subsidiary's chairman, allowing him to resume duties [4] - Qingmu Technology plans to acquire 65.83% of Vitalis Pharma AS for 300 million Norwegian Krone (approximately 212 million yuan) [4] - Anda Intelligent's shareholder plans to reduce its stake by up to 2.74% [4] Group 4 - Wansheng Intelligent is a candidate for a project with a pre-bid amount of approximately 42.99 million yuan, representing 4.56% of its audited revenue for 2024 [4] - Yipin Hong received a drug registration certificate for a medication used to treat Alzheimer's symptoms [4] Group 5 - *ST Sansheng received a total of 254 million yuan from restructuring investors [4] - Haichuang Pharmaceutical received approval for clinical trials of HP518 tablets for advanced prostate cancer treatment [4] Group 6 - Ningbo Huaxiang's subsidiary plans to invest 5 million yuan in a venture capital fund focusing on intelligent industries [4] - Petty Co. plans to repurchase shares worth 50 to 70 million yuan [4] Group 7 - Tongji Technology's subsidiary won a construction project with a bid price of 866 million yuan [4] - Prolo Pharmaceutical received a drug registration certificate for a generic drug [4] Group 8 - Jingyan Technology plans to use up to 1.6 billion yuan of idle funds for financial management [4] - Furan De received government subsidies totaling 34.65 million yuan [4] Group 9 - David Medical's subsidiary's medical device registration has been accepted [4] - Jusaylong plans to increase its subsidiary's capital by 170 million yuan through debt-to-equity conversion [4] Group 10 - Heng Rui Pharmaceutical's application for a drug license has been accepted by the National Medical Products Administration [4] - Lege Co. plans to increase its stake in the company by 40 to 80 million yuan [4] Group 11 - New Beiyang's subsidiary won a project with the Bank of Communications [4] - Jiangxi Changyun plans to publicly transfer land use rights and buildings with a starting price of 7.79 million yuan [4] Group 12 - Shenqi Pharmaceutical's subsidiary has paid approximately 16.67 million yuan in tax and penalties [4] - Panjiang Co. plans to invest 1.334 billion yuan in a power plant project [4] Group 13 - Fashilong's vice president resigned for personal reasons [4] - Chunxue Food received government subsidies of 3.79 million yuan [4] Group 14 - China Galaxy completed the repayment of a short-term financing bond totaling 3.025 billion yuan [4] - Jiuzhou Pharmaceutical received approval for a chemical raw material drug [4] Group 15 - Longqi Technology's subsidiary plans to invest 30 million yuan in a venture capital fund [4]

Core Viewpoint - The company Furan De (605050.SH) announced that it received government subsidies totaling 34.655 million yuan from January 1, 2025, to November 24, 2025, which represents 10.94% of the audited net profit attributable to shareholders for the fiscal year 2024 [1] Summary by Category - **Government Subsidies** - The total amount of government subsidies received is 34.655 million yuan [1] - Of this, 23.355 million yuan is related to income, while 11.300 million yuan is related to assets [1] - **Financial Impact** - The government subsidies account for 10.94% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1]